These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1576 related articles for article (PubMed ID: 24612209)
21. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. Dean KE; Hikaka J; Huakau JT; Walmsley RS J Gastroenterol Hepatol; 2012 Mar; 27(3):487-92. PubMed ID: 22098019 [TBL] [Abstract][Full Text] [Related]
22. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208 [TBL] [Abstract][Full Text] [Related]
23. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis]. Mocciaro F; Orlando A; Scimeca D; Cottone M Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405 [TBL] [Abstract][Full Text] [Related]
24. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres. Landy J; Wahed M; Peake ST; Hussein M; Ng SC; Lindsay JO; Hart AL J Crohns Colitis; 2013 Dec; 7(11):e516-21. PubMed ID: 23623737 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P; J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996 [TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population. Juliao F; Marquez J; Aristizabal N; Yepes C; Zuleta J; Gisbert JP Digestion; 2013; 88(4):222-8. PubMed ID: 24281150 [TBL] [Abstract][Full Text] [Related]
28. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. Schmidt KJ; Müller N; Dignass A; Baumgart DC; Lehnert H; Stange EF; Herrlinger KR; Fellermann K; Büning J J Crohns Colitis; 2016 Jan; 10(1):31-7. PubMed ID: 26419459 [TBL] [Abstract][Full Text] [Related]
29. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis. Zhou Z; Dai C; Liu WX Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055 [TBL] [Abstract][Full Text] [Related]
30. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220 [TBL] [Abstract][Full Text] [Related]
31. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817 [TBL] [Abstract][Full Text] [Related]
32. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. Miyoshi J; Matsuoka K; Inoue N; Hisamatsu T; Ichikawa R; Yajima T; Okamoto S; Naganuma M; Sato T; Kanai T; Ogata H; Iwao Y; Hibi T J Crohns Colitis; 2013 Dec; 7(12):e609-14. PubMed ID: 23680174 [TBL] [Abstract][Full Text] [Related]
33. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Rosen MJ; Minar P; Vinks AA Aliment Pharmacol Ther; 2015 Jun; 41(11):1094-103. PubMed ID: 25809869 [TBL] [Abstract][Full Text] [Related]
34. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. Monterubbianesi R; Aratari A; Armuzzi A; Daperno M; Biancone L; Cappello M; Annese V; Riegler G; Orlando A; Viscido A; Meucci G; Gasbarrini A; Guidi L; Lavagna A; Sostegni R; Onali S; Papi C; Kohn A; J Crohns Colitis; 2014 Aug; 8(8):852-8. PubMed ID: 24472490 [TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C; Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873 [TBL] [Abstract][Full Text] [Related]